Genfit (NASDAQ: GNFT)
H1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-12 | ||||||
REV |
FY 2021 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 1.460 | ||||||
REV | 101.271M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Genfit (NASDAQ: GNFT) through any online brokerage.
Other companies in Genfit’s space includes: Graphite Bio (NASDAQ:GRPH), Jounce Therapeutics (NASDAQ:JNCE), Humanigen (NASDAQ:HGEN), Sesen Bio (NASDAQ:SESN) and Olema Pharmaceuticals (NASDAQ:OLMA).
The latest price target for Genfit (NASDAQ: GNFT) was reported by SVB Leerink on Monday, April 11, 2022. The analyst firm set a price target for 10.00 expecting GNFT to rise to within 12 months (a possible 204.88% upside). 3 analyst firms have reported ratings in the last year.
The stock price for Genfit (NASDAQ: GNFT) is $3.28 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Genfit.
Genfit’s H1 earnings are confirmed for Monday, September 12, 2022.
There is no upcoming split for Genfit.
Genfit is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.